Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

BTK Biological Pathways Reviews

Videos

John Allan, MD
Videos
08/18/2023

Featuring John Allan, MD

Featuring John Allan, MD
At the 2023 Great Debates & Updates in Hematologic Malignancies Meeting, John Allan, MD, analyzes the role of BTK inhibitors and combination therapies in the frontline treatment of patients with chronic lymphocytic leukemia.
At the 2023 Great Debates & Updates in Hematologic Malignancies Meeting, John Allan, MD, analyzes the role of BTK inhibitors and combination therapies in the frontline treatment of patients with chronic lymphocytic leukemia.
At the 2023 Great Debates &...
08/18/2023
Oncology
Susan M. O'Brien, MD
Videos
08/17/2023

Featuring Susan M. O'Brien, MD

Featuring Susan M. O'Brien, MD ...
Susan M. O'Brien, MD, discusses the possible applications of pirtobrutinib, a noncovalent BTK inhibitor, for the treatment of patients with CLL.
Susan M. O'Brien, MD, discusses the possible applications of pirtobrutinib, a noncovalent BTK inhibitor, for the treatment of patients with CLL.
Susan M. O'Brien, MD, discusses...
08/17/2023
Oncology
Ryan Jacobs, MD
Videos
12/13/2022
Ryan Jacobs, MD, discusses findings from a real-world analysis exploring BTK inhibitor-class switching in the first-line treatment of CLL and SLL, suggesting approximately 40% of patients who switch from ibrutinib to acalabrutinib experience...
Ryan Jacobs, MD, discusses findings from a real-world analysis exploring BTK inhibitor-class switching in the first-line treatment of CLL and SLL, suggesting approximately 40% of patients who switch from ibrutinib to acalabrutinib experience...
Ryan Jacobs, MD, discusses...
12/13/2022
Oncology
Dr Shadman
Videos
01/10/2022
Mayzar Shadman, MD, MPH, Seattle Cancer Care Alliance, highlights phase 2 Study of zanubrutinib in BTK Inhibitor-Intolerant patients with relapsed/refractory B-Cell malignancies, presented at the 2021 ASH Annual Meeting.
Mayzar Shadman, MD, MPH, Seattle Cancer Care Alliance, highlights phase 2 Study of zanubrutinib in BTK Inhibitor-Intolerant patients with relapsed/refractory B-Cell malignancies, presented at the 2021 ASH Annual Meeting.
Mayzar Shadman, MD, MPH, Seattle...
01/10/2022
Oncology
Michael Wang, MD, Talks LOXO-305 for MCL, WM
Videos
12/07/2020
In this video, Dr Wang discusses the use of LOXO-305, a highly selective BTK inhibitor, in patients with pretreated MCL, WM, and other NHLs.
In this video, Dr Wang discusses the use of LOXO-305, a highly selective BTK inhibitor, in patients with pretreated MCL, WM, and other NHLs.
In this video, Dr Wang discusses...
12/07/2020
Oncology
Nirav Shah, MD
Videos
08/05/2024
At the 2024 Pan Pacific Lymphoma Conference, Nirav Shah, MD, discusses innovation and the future development of cell therapies for patients with various types of B-cell malignancies.
At the 2024 Pan Pacific Lymphoma Conference, Nirav Shah, MD, discusses innovation and the future development of cell therapies for patients with various types of B-cell malignancies.
At the 2024 Pan Pacific Lymphoma...
08/05/2024
Oncology
Curtis Lachowiez, MD
Videos
08/05/2024
Curtis Lachowiez, MD, participated in a debate at the 2024 Great Debates and Updates meeting in which he argued in favor of triplet therapy for patients with acute myeloid leukemia who are unable to receive intensive induction chemotherapy.
Curtis Lachowiez, MD, participated in a debate at the 2024 Great Debates and Updates meeting in which he argued in favor of triplet therapy for patients with acute myeloid leukemia who are unable to receive intensive induction chemotherapy.
Curtis Lachowiez, MD,...
08/05/2024
Oncology
Videos
08/02/2024
Ticiana Leal, MD, discusses the course of treatment she would take for a patient with early-stage NSCLC.
Ticiana Leal, MD, discusses the course of treatment she would take for a patient with early-stage NSCLC.
Ticiana Leal, MD, discusses the...
08/02/2024
Oncology
Rene Adam, MD, PhD
Conference Coverage
08/02/2024
Rene Adam, MD, PhD, discusses results from the TRANSMET trial which demonstrated that liver transplantation combined with chemotherapy significantly improved survival among patients with unresectable colorectal liver metastases.
Rene Adam, MD, PhD, discusses results from the TRANSMET trial which demonstrated that liver transplantation combined with chemotherapy significantly improved survival among patients with unresectable colorectal liver metastases.
Rene Adam, MD, PhD, discusses...
08/02/2024
Oncology
Ajai Chari, MD
Videos
07/31/2024
Ajai Chari, MD, participated in a debate at the 2024 Great Debates & Updates meeting in which he argued in favor of using additional BCMA-directed therapy after prior BCMA-directed therapy for patients with multiple myeloma.
Ajai Chari, MD, participated in a debate at the 2024 Great Debates & Updates meeting in which he argued in favor of using additional BCMA-directed therapy after prior BCMA-directed therapy for patients with multiple myeloma.
Ajai Chari, MD, participated in...
07/31/2024
Oncology
Ajai Chari, MD
Videos
07/31/2024
Ajai Chari, MD, participated in a debate at the 2024 Great Debates & Updates meeting in which he argued against the use of stem cell transplantation for patients with multiple myeloma over the age of 65.
Ajai Chari, MD, participated in a debate at the 2024 Great Debates & Updates meeting in which he argued against the use of stem cell transplantation for patients with multiple myeloma over the age of 65.
Ajai Chari, MD, participated in...
07/31/2024
Oncology
Elizabeth Brem, MD
Videos
07/29/2024
Elizabeth Brem, MD, shares expert insight into a clinical trial examining elderly patients with DLBCL treated with rituximab and reduced dose cyclophosphamide, hydroxydaunorubicin, vincristine sulfate, and prednisone with or without oral...
Elizabeth Brem, MD, shares expert insight into a clinical trial examining elderly patients with DLBCL treated with rituximab and reduced dose cyclophosphamide, hydroxydaunorubicin, vincristine sulfate, and prednisone with or without oral...
Elizabeth Brem, MD, shares...
07/29/2024
Oncology
Elizabeth Brem, MD
Videos
07/29/2024
At the 2024 Great Debates & Updates meeting, Elizabeth Brem, MD, shares expert insight on the role of CAR T-cell therapies versus other novel therapies for treating older patients with relapsed diffuse large B-cell lymphoma.
At the 2024 Great Debates & Updates meeting, Elizabeth Brem, MD, shares expert insight on the role of CAR T-cell therapies versus other novel therapies for treating older patients with relapsed diffuse large B-cell lymphoma.
At the 2024 Great Debates &...
07/29/2024
Oncology
Rahul Banerjee, MD
Videos
07/28/2024
At the 2024 Great Debates & Updates meeting, Rahul Banerjee, MD, participated in a debate in which he argued against the use of CAR T-cell therapy in earlier lines of therapy among patients with multiple myeloma.
At the 2024 Great Debates & Updates meeting, Rahul Banerjee, MD, participated in a debate in which he argued against the use of CAR T-cell therapy in earlier lines of therapy among patients with multiple myeloma.
At the 2024 Great Debates &...
07/28/2024
Oncology
Amrita Krishnan, MD
Videos
07/28/2024
At the 2024 Great Debates & Updates meeting, Amrita Krishnan, MD, argued for the value of considering autologous stem cell transplantation for certain patients over the age of 65, emphasizing the benefit of assessing frailty as a complex and...
At the 2024 Great Debates & Updates meeting, Amrita Krishnan, MD, argued for the value of considering autologous stem cell transplantation for certain patients over the age of 65, emphasizing the benefit of assessing frailty as a complex and...
At the 2024 Great Debates &...
07/28/2024
Oncology
OLN

BTK

ALIASES

Bruton’s tyrosine kinase

Bruton's tyrosine kinase (BTK), a non-receptor tyrosine kinase, plays an important role in B-cell receptor activation.1 BCR activation results in translocation and phosphorylation of BTK. When BTK is inducted it activates phospholipase C and calcium mobilization, which results in downstream events, including proliferation, maturation, differentiation, and survival.2

Understanding the Role of BTK

Resources

News
11/28/2023

Jordan Kadish

Jordan Kadish
BTK inhibitor ibrutinib maintenance following induction chemo-immunotherapy was feasible and demonstrated manageable safety among certain patients with treatment-naive mantle cell lymphoma.
BTK inhibitor ibrutinib maintenance following induction chemo-immunotherapy was feasible and demonstrated manageable safety among certain patients with treatment-naive mantle cell lymphoma.
BTK inhibitor ibrutinib...
11/28/2023
Oncology
News
11/03/2023

Jordan Kadish

Jordan Kadish
A regimen consisting of obinutuzumab, ibrutinib, and venetoclax demonstrated promising sustained remission among patients with high-risk chronic lymphocytic leukemia with del(17p) and/or TP53 mutation, according to a final analysis of the...
A regimen consisting of obinutuzumab, ibrutinib, and venetoclax demonstrated promising sustained remission among patients with high-risk chronic lymphocytic leukemia with del(17p) and/or TP53 mutation, according to a final analysis of the...
A regimen consisting of...
11/03/2023
Oncology
News
09/27/2023

Jordan Kadish

Jordan Kadish
BTK inhibitor zanubrutinib exhibited similar efficacy and improved safety compared to ibrutinib among patients with Waldenström macroglobulinemia, according to a final analysis of the phase 3 ASPEN trial.
BTK inhibitor zanubrutinib exhibited similar efficacy and improved safety compared to ibrutinib among patients with Waldenström macroglobulinemia, according to a final analysis of the phase 3 ASPEN trial.
BTK inhibitor zanubrutinib...
09/27/2023
Oncology
News
09/21/2023

Jordan Kadish

Jordan Kadish
A phase 2 trial found that ibrutinib plus rituximab demonstrated efficacy among patients with CLL and steroid refractory autoimmune cytopenias such as autoimmune hemolytic anemia and pure red cell aplasia.
A phase 2 trial found that ibrutinib plus rituximab demonstrated efficacy among patients with CLL and steroid refractory autoimmune cytopenias such as autoimmune hemolytic anemia and pure red cell aplasia.
A phase 2 trial found that...
09/21/2023
Oncology
News
09/01/2023

Jordan Kadish

Jordan Kadish
BTK inhibitor ibrutinib plus BCL-2 inhibitor venetoclax improved progression-free survival among older or comorbid patients with previously untreated chronic lymphocytic leukemia vs treatment with chlorambucil and obinutuzumab.
BTK inhibitor ibrutinib plus BCL-2 inhibitor venetoclax improved progression-free survival among older or comorbid patients with previously untreated chronic lymphocytic leukemia vs treatment with chlorambucil and obinutuzumab.
BTK inhibitor ibrutinib plus...
09/01/2023
Oncology
News
08/02/2023

Jordan Kadish

Jordan Kadish
Patients with high BCL2/MYC coexpression non-GCB DLBCL may demonstrate improved event-free survival from the addition of BTK inhibitor ibrutinib to R-CHOP treatment, according to an analysis of the phase 3 PHOENIX trial.
Patients with high BCL2/MYC coexpression non-GCB DLBCL may demonstrate improved event-free survival from the addition of BTK inhibitor ibrutinib to R-CHOP treatment, according to an analysis of the phase 3 PHOENIX trial.
Patients with high BCL2/MYC...
08/02/2023
Oncology
News
07/17/2023

Jordan Kadish

Jordan Kadish
According to a phase 2 trial, the combination of nivolumab and BTK inhibitor ibrutinib is an active and safe regimen among patients with diffuse large B-cell lymphoma Richter transformation.
According to a phase 2 trial, the combination of nivolumab and BTK inhibitor ibrutinib is an active and safe regimen among patients with diffuse large B-cell lymphoma Richter transformation.
According to a phase 2 trial,...
07/17/2023
Oncology
News
06/08/2023

Jordan Kadish

Jordan Kadish
The real-world response rates among patients with CLL/SLL after receiving covalent BTK inhibitor and B-cell lymphoma 2 inhibitor treatment demonstrate a need for more effective follow-up therapies, according to a retrospective real-world...
The real-world response rates among patients with CLL/SLL after receiving covalent BTK inhibitor and B-cell lymphoma 2 inhibitor treatment demonstrate a need for more effective follow-up therapies, according to a retrospective real-world...
The real-world response rates...
06/08/2023
Oncology
News
06/06/2023

Jordan Kadish

Jordan Kadish
A phase 3 trial indicated that acalabrutinib with or without obinutuzumab resulted in improved quality-adjusted time without symptoms and toxicity vs chlorambucil plus obinutuzumab for patients with previously untreated CLL.
A phase 3 trial indicated that acalabrutinib with or without obinutuzumab resulted in improved quality-adjusted time without symptoms and toxicity vs chlorambucil plus obinutuzumab for patients with previously untreated CLL.
A phase 3 trial indicated that...
06/06/2023
Oncology
News
05/01/2023

Jordan Kadish

Jordan Kadish
Findings from a multicenter real-world retrospective analysis indicate that BTK inhibitor ibrutinib demonstrated good efficacy among patients with heavily pretreated R/R mantle cell lymphoma.
Findings from a multicenter real-world retrospective analysis indicate that BTK inhibitor ibrutinib demonstrated good efficacy among patients with heavily pretreated R/R mantle cell lymphoma.
Findings from a multicenter...
05/01/2023
Oncology
News
08/08/2024
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study...
08/08/2024
Oncology
FDA Approval
08/08/2024
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug...
08/08/2024
Oncology
News
08/07/2024
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the...
08/07/2024
Oncology
News
08/07/2024
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that...
08/07/2024
Oncology
News
08/07/2024
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study...
08/07/2024
Oncology
FDA Approval
08/06/2024
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO...
08/06/2024
Oncology
FDA Approval
08/02/2024
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food...
08/02/2024
Oncology
FDA Approval
08/01/2024
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab...
08/01/2024
Oncology
News
08/01/2024
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of...
08/01/2024
Oncology
News
08/01/2024
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the...
08/01/2024
Oncology

Podcasts

Episode 2: BTK Inhibitors for CLL and Lymphomas
Podcasts
07/03/2020
On this episode of Blood Bytes, John Leonard, MD, and Richard Furman, MD, discuss BTK inhibitors for the treatment of CLL and lymphomas.
On this episode of Blood Bytes, John Leonard, MD, and Richard Furman, MD, discuss BTK inhibitors for the treatment of CLL and lymphomas.
On this episode of Blood Bytes,...
07/03/2020
Oncology
BTK Inhibitors Important in the Treatment Landscape of MCL
Podcasts
01/23/2020
Michael Wang, MD, discusses the importance of BTK inhibitors for the treatment of patients with MCL.
Michael Wang, MD, discusses the importance of BTK inhibitors for the treatment of patients with MCL.
Michael Wang, MD, discusses the...
01/23/2020
Oncology
Petros Grivas, MD, PhD, Fred Hutchinson Cancer Center
Podcasts
03/07/2024

Featured Petros Grivas, MD, PhD

Featured Petros Grivas, MD, PhD ...
Petros Grivas, MD, PhD, shares results from the phase 2 TROPHY-U-01 study evaluating sacituzumab govetican plus pembrolizumab among patients with metastatic urothelial carcinoma following progression on platinum-chemotherapy.
Petros Grivas, MD, PhD, shares results from the phase 2 TROPHY-U-01 study evaluating sacituzumab govetican plus pembrolizumab among patients with metastatic urothelial carcinoma following progression on platinum-chemotherapy.
Petros Grivas, MD, PhD, shares...
03/07/2024
Oncology
Sara Hurvitz, MD, David Geffen School of Medicine – UCLA, Los Angeles, CA
Podcasts
02/16/2023
Sara Hurvitz, MD, shares how she would treat a patient with early stage HER2-positive breast cancer.
Sara Hurvitz, MD, shares how she would treat a patient with early stage HER2-positive breast cancer.
Sara Hurvitz, MD, shares how she...
02/16/2023
Oncology
Michael Hall, MD, Fox Chase Cancer Center
Podcasts
12/20/2022
Michael Hall, MD, reviews his presentation from the 2022 Great Debates & Updates in Gastrointestinal Malignancies virtual meeting, on genetic testing for gastrointestinal cancers.
Michael Hall, MD, reviews his presentation from the 2022 Great Debates & Updates in Gastrointestinal Malignancies virtual meeting, on genetic testing for gastrointestinal cancers.
Michael Hall, MD, reviews his...
12/20/2022
Oncology
Petros Grivas, MD, PhD, Fred Hutchinson Cancer Center
Podcasts
11/15/2022
Petros Grivas, MD, PhD, shares how he would treat a patient who presented with a new diagnosis of metastatic urothelial cancer and progressed after completing a gemcitabine-cisplatin chemotherapy regimen.
Petros Grivas, MD, PhD, shares how he would treat a patient who presented with a new diagnosis of metastatic urothelial cancer and progressed after completing a gemcitabine-cisplatin chemotherapy regimen.
Petros Grivas, MD, PhD, shares...
11/15/2022
Oncology
OLN favicon
Podcasts
07/29/2022
Margherita Rimini, MD, discusses findings from an analysis exploring the association between the BRCAness phenotype and response to platinum-based chemotherapy among patients with intrahepatic cholangiocarcinoma.
Margherita Rimini, MD, discusses findings from an analysis exploring the association between the BRCAness phenotype and response to platinum-based chemotherapy among patients with intrahepatic cholangiocarcinoma.
Margherita Rimini, MD, discusses...
07/29/2022
Oncology
Ruth He, MD, Lombardi Comprehensive Cancer Center
Podcasts
07/22/2022
Ruth He, MD, discusses findings from a subgroup analysis which evaluated outcomes of patients with biliary tract cancer receiving durvalumab plus chemotherapy by primary tumor location: intrahepatic or extrahepatic cholangiocarcinoma or...
Ruth He, MD, discusses findings from a subgroup analysis which evaluated outcomes of patients with biliary tract cancer receiving durvalumab plus chemotherapy by primary tumor location: intrahepatic or extrahepatic cholangiocarcinoma or...
Ruth He, MD, discusses findings...
07/22/2022
Oncology
Arndt Vogel, MD, Hannover Medical School
Podcasts
07/14/2022
Arndt Vogel, MD, shares results from the phase 2, FIGHT-202 trial which evaluated pemigatinib in patients with previously treated, locally advanced or metastatic cholangiocarcinoma.
Arndt Vogel, MD, shares results from the phase 2, FIGHT-202 trial which evaluated pemigatinib in patients with previously treated, locally advanced or metastatic cholangiocarcinoma.
Arndt Vogel, MD, shares results...
07/14/2022
Oncology
Petros Grivas, MD, Fred Hutchinson Cancer Center
Podcasts
06/22/2022
Petros Grivas, MD, shares results from the phase 2 TROPHY-U-01 trial evaluating the sacituzumab govitecan in combination with pembrolizumab for patients with metastatic urothelial cancer who progressed after platinum-based regimens.
Petros Grivas, MD, shares results from the phase 2 TROPHY-U-01 trial evaluating the sacituzumab govitecan in combination with pembrolizumab for patients with metastatic urothelial cancer who progressed after platinum-based regimens.
Petros Grivas, MD, shares...
06/22/2022
Oncology
Robert Jones, MD
Podcasts
06/21/2022
Robert Jones, MD, shares results and insights from the phase 2 ATLANTIS trial, evaluating maintenance cabozantinib following platinum-based chemotherapy for patients with metastatic urothelial carcinoma.
Robert Jones, MD, shares results and insights from the phase 2 ATLANTIS trial, evaluating maintenance cabozantinib following platinum-based chemotherapy for patients with metastatic urothelial carcinoma.
Robert Jones, MD, shares results...
06/21/2022
Oncology
David O'Malley
Podcasts
06/20/2022
In part 2 of this 2-part podcast series, David O'Malley, MD, Ohio State University, discusses strategies for overcoming PARP inhibitor and platinum resistance in patients with ovarian cancer.
In part 2 of this 2-part podcast series, David O'Malley, MD, Ohio State University, discusses strategies for overcoming PARP inhibitor and platinum resistance in patients with ovarian cancer.
In part 2 of this 2-part podcast...
06/20/2022
Oncology

Interactive

Quiz
09/01/2023
True or False: Results of the phase 3 GLOW trial indicated that ibrutinib plus venetoclax treatment did not improve progression-free survival compared to treatment with chlorambucil and obinutuzumab among older patients with previously...
True or False: Results of the phase 3 GLOW trial indicated that ibrutinib plus venetoclax treatment did not improve progression-free survival compared to treatment with chlorambucil and obinutuzumab among older patients with previously...
True or False: Results of the...
09/01/2023
Oncology
Quiz
05/08/2023
In a study assessing the efficacy and safety of BTK inhibitor DTRMWXHS-12 plus everolimus and pomalidomide among 32 patients with hematologic malignancies, how many patients were highly responsive to this treatment?
In a study assessing the efficacy and safety of BTK inhibitor DTRMWXHS-12 plus everolimus and pomalidomide among 32 patients with hematologic malignancies, how many patients were highly responsive to this treatment?
In a study assessing the...
05/08/2023
Oncology
Quiz
02/27/2023
True or False: According to a phase 3 study, zanubritinib treatment for patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia yielded superior progression free survival and overall remission rates when...
True or False: According to a phase 3 study, zanubritinib treatment for patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia yielded superior progression free survival and overall remission rates when...
True or False: According to a...
02/27/2023
Oncology
Quiz
08/08/2024
Do you know whether maintenance selinexor demonstrated promising efficacy and safety among patients with advanced or first-line recurrent TP53 wild-type endometrial cancer?
Do you know whether maintenance selinexor demonstrated promising efficacy and safety among patients with advanced or first-line recurrent TP53 wild-type endometrial cancer?
Do you know whether maintenance...
08/08/2024
Oncology
Quiz
08/08/2024
Based on results from the phase 3 RUBY trial, the FDA expanded the approval of dostarlimab plus chemotherapy to include all patients with primary advanced or recurrent endometrial cancer. Do you know what the recommended dose of dostarlimab...
Based on results from the phase 3 RUBY trial, the FDA expanded the approval of dostarlimab plus chemotherapy to include all patients with primary advanced or recurrent endometrial cancer. Do you know what the recommended dose of dostarlimab...
Based on results from the phase...
08/08/2024
Oncology
Quiz
08/05/2024
True or False: According to results from the phase 3 SWOG S127 study, the addition of everolimus, an mTOR inhibitor, to endocrine therapy did not improve survival outcomes among patients with high-risk, hormone receptor (HR)-positive,...
True or False: According to results from the phase 3 SWOG S127 study, the addition of everolimus, an mTOR inhibitor, to endocrine therapy did not improve survival outcomes among patients with high-risk, hormone receptor (HR)-positive,...
True or False: According to...
08/05/2024
Oncology
Quiz
07/15/2024
According to the final analysis of the phase 2 ATEMPT trial, which of the following therapies demonstrated more favorable long-term outcomes among patients with HER2-positive early-stage invasive breast cancer?
According to the final analysis of the phase 2 ATEMPT trial, which of the following therapies demonstrated more favorable long-term outcomes among patients with HER2-positive early-stage invasive breast cancer?
According to the final analysis...
07/15/2024
Oncology
Quiz
06/28/2024
True or False: As reported in the phase 3 PEARLY trial, the addition of carboplatin to standard anthracycline and taxane therapy significantly improved event-free survival among patients with early-stage triple-negative breast cancer (TNBC).
True or False: As reported in the phase 3 PEARLY trial, the addition of carboplatin to standard anthracycline and taxane therapy significantly improved event-free survival among patients with early-stage triple-negative breast cancer (TNBC).
True or False: As reported in...
06/28/2024
Oncology
Quiz
06/26/2024
What adjuvant treatment would you recommend?
What adjuvant treatment would you recommend?
What adjuvant treatment would...
06/26/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement